In the last trading session, 2.0 million Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares changed hands as the company’s beta touched -0.58. With the company’s per share price at $7.03 changed hands at $0.33 or 4.93% during last session, the market valuation stood at $493.68M. AMLX’s last price was a discount, traded about -183.78% off its 52-week high of $19.95. The share price had its 52-week low at $1.58, which suggests the last value was 77.52% up since then. When we look at Amylyx Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.4 million shares, with the 3-month average coming to 1.32 million.
Analysts gave the Amylyx Pharmaceuticals Inc (AMLX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.33. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AMLX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Amylyx Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.53.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information
Instantly AMLX was in green as seen at the end of in last trading. With action 23.33%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -52.24%, with the 5-day performance at 23.33% in the green. However, in the 30-day time frame, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) is 98.03% up. Looking at the short shares, we see there were 1.01 million shares sold at short interest cover period of 0.76 days.
The consensus price target for the stock as assigned by Wall Street analysts is 4, meaning bulls need a downside of -75.75% from its current market value. According to analyst projections, AMLX’s forecast low is 3 with 10 as the target high. To hit the forecast high, the stock’s price needs a -42.25% plunge from its current level, while the stock would need to tank 57.33% for it to hit the projected low.
Amylyx Pharmaceuticals Inc (AMLX) estimates and forecasts
Data shows that the Amylyx Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 286.26% over the past 6 months, a -650.00% in annual growth rate that is considerably lower than the industry average of 18.20%. Year-over-year growth is forecast to reach -77.00% down from the last financial year.
The company’s revenue for the corresponding quarters a year ago was 108.45M and 88.64M respectively.
The 2024 estimates are for Amylyx Pharmaceuticals Inc earnings to decrease by -704.52%.
AMLX Dividends
Amylyx Pharmaceuticals Inc is expected to release its next quarterly earnings report in December.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 14.32% of Amylyx Pharmaceuticals Inc shares while 93.68% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 109.34%. There are 93.68% institutions holding the Amylyx Pharmaceuticals Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 6.2251% of the shares, roughly 4.22 million AMLX shares worth $8.03 million.
AQR CAPITAL MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 4.9237% or 3.34 million shares worth $6.35 million as of 2024-06-30.
